title: Regression of the inflammatory microenvironment of the peritoneal cavity in women with endometriosis by GnRHa treatment.
abstract: OBJECTIVE
  To investigate the effect of gonadotropin-releasing hormone analogues (GnRHa) on the peritoneal fluid microenvironment in women with endometriosis.
  
  
  METHODS
  Peritoneal fluid was collected from 85 women with severe endometriosis (rAFS stage III and IV) during laparoscopic surgery during the proliferative phase. Prior to surgery clinical data were collected. The concentrations of specific markers for endometriosis in the peritoneal fluid were determined using an ELISA and a comparison between peritoneal fluid markers in women using GnRHa and no hormonal treatment was performed using a non-parametric Mann-Whitney U test.
  
  
  RESULTS
  The study included peritoneal fluid from 39 patients who had been administered GnRHa (Zoladex(®)) in the three months prior to surgery and 46 from women with no hormonal treatment in this period. Concentrations of IL-8, PAPP-A, glycodelin-A and midkine were significantly reduced in the GnRHa treatment group compared to women receiving no hormonal treatment. RANTES, MCP-1, ENA-78, TNF-α, OPG, IP-10 and defensin showed no significant change between the two groups.
  
  
  CONCLUSIONS
  GnRHa mediate a significant regression in the inflammatory nature of the peritoneal microenvironment in women with endometriosis.
authors.affiliation: Department of Obstetrics and Gynaecology, Inselspital, University of Berne, Berne, Switzerland. Electronic address: kw.nirgianakis@gmail.com.
authors.forename: K
authors.initials: K
authors.lastname: Nirgianakis
authors.forename: N A
authors.initials: NA
authors.lastname: Bersinger
authors.forename: B
authors.initials: B
authors.lastname: McKinnon
authors.forename: P
authors.initials: P
authors.lastname: Kostov
authors.forename: S
authors.initials: S
authors.lastname: Imboden
authors.forename: M D
authors.initials: MD
authors.lastname: Mueller
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D001202:Ascitic Fluid / Q000473:pathology*; D016022:Case-Control Studies; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000097:blood; D004715:Endometriosis / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000627:therapeutic use*; D017273:Goserelin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D015854:Up-Regulation / Q000502:physiology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D016207:Cytokines; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone
keywords: Cytokines; Endometriosis; GnRH agonists; Peritoneal fluid